Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lacey

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Medical Economics|August 4, 2012
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrelTanya M Burton, Michael Lacey, Fang Liu, et al.
Kidney International|April 23, 2025
B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathyIzabella Z A Pawluczyk, Jasraj S Bhachu, Jeremy R Brown, et al.
Heart (British Cardiac Society)|December 23, 2017
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fractionJohn J V McMurray, David Trueman, Elizabeth Hancock, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Medical Economics|August 4, 2012
One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrelTanya M Burton, Michael Lacey, Fang Liu, et al.
Kidney International|April 23, 2025
B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathyIzabella Z A Pawluczyk, Jasraj S Bhachu, Jeremy R Brown, et al.
Heart (British Cardiac Society)|December 23, 2017
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fractionJohn J V McMurray, David Trueman, Elizabeth Hancock, et al.
Pageof 2